SAB Biotherapeutics

What SAB Biotherapeutics does

SAB Biotherapeutics (NASDAQ: SABS), commonly branded SAB BIO, is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Miami Beach, Florida, with a research and development campus in Sioux Falls, South Dakota. The company is built around a single proprietary technology platform — Tc-Bovine transchromosomic cattle — which is genetically engineered to produce fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. Across seven clinical trials dosing 700 individuals, SAB BIO reports zero cases of serum sickness and zero neutralizing anti-drug antibodies, supporting a differentiated safety and redosing profile relative to existing rabbit-derived anti-thymocyte globulin comparators.

The company's lead clinical asset is SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) being developed as a disease-modifying immunotherapy for newly diagnosed Stage 3 Type 1 Diabetes (T1D) patients aged 5–40, with the goal of preserving pancreatic beta cell function and C-peptide production rather than managing insulin symptoms. SAB-142 is currently in the registrational Phase 2b SAFEGUARD trial across approximately 65 global sites, with topline data expected in the second half of 2027. Beyond SAB-142, the Tc-Bovine platform underpins a broader pipeline of hIgG candidates for additional immune and autoimmune disorders, and clinical data has been presented at ADA, FOCIS, ISPAD, and the Immunology of Diabetes Society Congress.

SAB Biotherapeutics is publicly traded, has 51–100 employees, and operates a pre-commercial, partnership- and capital-driven business model with no marketed products and no recurring product revenue. The company has funded operations primarily through equity financings — including a $130M preferred-stock placement led by RA Capital Management (Oct 2023), a $175M private placement led by Sanofi and Blackstone (Jul 2025), and an $85M underwritten public offering (Mar 2026) — alongside historical U.S. Department of Defense COVID-19 contract closeout payments. Manufacturing is outsourced to Emergent BioSolutions Canada under a five-year exclusive agreement, and SAB relies on investor conferences, scientific congresses, and sell-side analyst coverage to support future commercial launch of SAB-142.

Name

SAB Biotherapeutics

Legal name

SAB Biotherapeutics, Inc.

Website

https://sab.bio

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a fully human multi-specific anti-thymocyte globulin for newly diagnosed Stage 3 Type 1 Diabetes, produced via its proprietary Tc-Bovine transchromosomic cattle platform.

Ownership category

akta.pro rank

Headquarters

HQ city

Miami

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Future product sales of SAB-142: Clinical-stage biopharmaceutical company with no marketed products; future recurring/one-time revenue expected from commercial launch of SAB-142 (and follow-on pipeline candidates) for Stage 3 Type 1 Diabetes and other autoimmune indications. Estimated adjusted peak U.S. revenue potential of approximately $2.2 billion (with 45% probability of success) per Jefferies initiation.
2. Government and defense contract funding: Historical government contract revenue from the U.S. Department of Defense for COVID-19 prototype research (final closeout settlement of $16.8 million, with an $8.2 million tranche received in January 2023).

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

Core offering

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing SAB-142, a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy for Stage 3 Type 1 Diabetes (T1D). SAB-142 is produced using the company's proprietary Tc-Bovine transchromosomic cattle platform, which generates fully human, multi-specific polyclonal immunoglobulin G (hIgG) antibodies without requiring human donors or convalescent plasma. The lead asset is currently being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40, with topline data expected in 2H 2027.

Product overview

SAB Biotherapeutics (SAB BIO) is a clinical-stage biopharmaceutical company that operates a single integrated platform-plus-lead-asset architecture: its proprietary Tc-Bovine transchromosomic cattle platform produces fully human, multi-specific polyclonal antibodies (hIgG), and that platform's lead output is the drug candidate SAB-142, a fully human anti-thymocyte globulin (hATG) currently in a registrational Phase 2b SAFEGUARD trial for Stage 3 type 1 diabetes. The Tc-Bovine platform underpins all of SAB BIO's hIgG therapeutic candidates, while SAB-142 represents the most advanced clinical program derived from that platform.

Differentiator

Problem solved

Functional benefit

Products and services

• SAB-142 SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) disease-modifying immunotherapy being developed to delay the onset and progression of Stage 3 Type 1 Diabetes (T1D). It modulates multiple immune cells involved in destroying pancreatic beta cells, with the goal of preserving C-peptide and enabling life-long redosing with a superior safety profile (no serum sickness, low/no immunogenicity). It is being evaluated in the registrational Phase 2b SAFEGUARD trial in newly diagnosed adult, adolescent, and pediatric T1D patients aged 5-40.

Quantifiable outcome

• 700 individuals dosed across 7 clinical trials with zero serum sickness and zero neutralizing anti-drug antibodies
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Emergent BioSolutions Canada Inc.flagshipStrategic or Co-development Partner · 28 April 2026Five-year Master Manufacturing Services Agreement signed April 28, 2026, under which Emergent BioSolutions Canada will perform clinical and commercial manufacturing of SAB-142 at its Winnipeg, Manitoba facility. Emergent holds sole and exclusive manufacturing rights during the term, with SAB reserving rights to contract an alternative source in limited circumstances. The deal is valued at approximately $50 million, with $36 million contingent on future regulatory approval and downstream milestones; represents a minimum aggregate spend commitment over five years from FDA approval.
• Clinical Advisory Board (Cardiff University, University of Florida, UCSF, University of Melbourne, KU Leuven, University of Miami, Royal Melbourne Hospital)coreStrategic or Co-development Partner · 1 January 2026Advisory partnership with leading T1D key opinion leaders across major academic institutions including Colin Mark Dayan (Cardiff), Michael Haller (U Florida), Stephen Gitelman (UCSF), Thomas Kay (U Melbourne), Chantal Mathieu (KU Leuven), Jay S. Skyler (U Miami), and John Wentworth (Royal Melbourne Hospital). The Clinical Advisory Board guides SAB BIO on SAB-142 clinical development.
• U.S. Department of DefensecoreOthers · 18 January 2023Government partner on a COVID-19 prototype research contract that delivered a final closeout settlement of $16.8 million, including an additional $8.2 million tranche received in January 2023. The relationship supported SAB BIO's development of anti-COVID-19 hIgG therapeutics.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Provention Bio (acquired by Sanofi): Acquired by Sanofi in 2023 for its lead asset teplizumab (Tzield), a disease-modifying anti-CD3 therapy approved for Stage 2 Type 1 Diabetes. Direct therapeutic competitor to SAB-142 in the disease-modifying T1D space and validates the strategic value SAB BIO is pitching to Sanofi as an investor.
• ViaCyte: Clinical-stage developer of stem cell-derived beta cell replacement therapies (e.g., VC-02, partnered with CRISPR Therapeutics) for Type 1 Diabetes. Targets the same newly diagnosed T1D population with a complementary cell-based rather than antibody-based mechanism.

Broad incumbents

• Vertex Pharmaceuticals: Late-stage developer of VX-880/zimislecel, a stem cell-derived islet cell therapy for Type 1 Diabetes. Competes for the same newly diagnosed T1D patient population with a different disease-modifying mechanism (cell replacement vs. immune modulation).
• Sanofi: Global biopharma with approved Tzield (teplizumab) for Stage 2 T1D and strategic investor in SAB BIO's July 2025 $175M placement. The most important incumbent in disease-modifying T1D and a likely acquirer or commercial partner if SAB-142 succeeds.
• Eli Lilly: Major diabetes incumbent with broad insulin franchise (Humalog, Lyumjev) and acquired Sigilon Therapeutics for T1D cell therapy development. Overlaps in T1D therapeutics broadly and represents a potential strategic acquirer of SAB BIO given the SIG-002 platform bet.
• Novo Nordisk: Global diabetes leader with the broadest insulin portfolio (NovoLog, Levemir, Tresiba, Fiasp) and ongoing T1D R&D. Operates in the same patient population SAB-142 targets but with symptom-management rather than disease-modifying therapies.

Emerging players

• Dompé Farmaceutici: Italian biopharma developing ladarixin, an oral IL-8 inhibitor in clinical trials for new-onset Type 1 Diabetes. Emerging disease-modifying T1D player with similar Phase 2/3 trial positioning but a small-molecule rather than polyclonal antibody approach.
• Sigilon Therapeutics (acquired by Eli Lilly): Developed encapsulated cell therapies for Type 1 Diabetes (SIG-002) using Afibromer technology; acquired by Eli Lilly in 2023. Competes in the same T1D disease-modifying space via cell encapsulation rather than antibody-mediated immune modulation.
• Zealand Pharma: Clinical-stage developer of dasiglucagon (ready-to-use glucagon) for T1D hypoglycemia rescue and broader metabolic disease pipeline. Overlaps with SAB BIO in the T1D therapeutics market with an adjacent (hypoglycemia) rather than disease-modifying focus.

Others

• Grifols: Global plasma-derived immunoglobulin leader (Gamunex, Flebogamma) and SAB BIO's most direct infrastructure counterpart given SAB's reliance on Emergent BioSolutions (a competing plasma/biologics CDMO) for manufacturing. Comparable as a plasma-derived immunoglobulin platform incumbent though focused on replacement IgG therapy rather than polyclonal immune modulation.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/SABBantibody

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds9 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SAB Biotherapeutics